Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Genetic ancestry in population pharmacogenomics unravels distinct geographical patterns related to drug toxicity

  • Karamperis, Kariofyllis
  • Katz, Sonja
  • Melograna, Federico
  • Ganau, Francesc P.
  • Van Steen, Kristel
  • Patrinos, George P.
  • Lao, Oscar
Genetic ancestry plays a major role in pharmacogenomics, and a deeper understanding of the genetic diversity among individuals holds immerse promise for reshaping personalized medicine. In this pivotal study, we have conducted a large-scale genomic analysis of 1,136 pharmacogenomic variants employing machine learning algorithms on 3,714 individuals from publicly available datasets to assess the risk proximity of experiencing drug-related adverse events. Our findings indicate that Admixed Americans and Europeans have demonstrated a higher risk of experiencing drug toxicity, whereas individuals with East Asian ancestry and, to a lesser extent, Oceanians displayed a lower risk proximity. Polygenic risk scores for drug-gene interactions did not necessarily follow similar assumptions, reflecting distinct genetic patterns and population-specific differences that vary depending on the drug class. Overall, our results provide evidence that genetic ancestry is a pivotal factor in population pharmacogenomics and should be further exploited to strengthen even more personalized drug therapy., GP gratefully acknowledges the funding from the European Union’s Horizon 2020 research and Innovation Programme under the Marie Sklodowska-Curie Grant Agreements No 813533 (MLFPM) and No 860895 (TranSYS), the FNRS convention PDR T.0294.24 “Expanded PRS embracing pathways and interactions for increased clinical utility. O.L. gratefully acknowledges the financial support from the Engineering and Physical Sciences Research Council of UK [grant number EP/X025160/1]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Machine learning in Alzheimer's disease genetics

  • Bracher-Smith, Matthew
  • Pérez-Tur, Jordi
  • Bullido, María Jesús
  • Mir, Pablo
  • Escott-Price, Valentina
16 páginas, 4 figuras, 2 tablas., raditional statistical approaches have advanced our understanding of the genetics of complex diseases, yet are limited to linear additive models. Here we applied machine learning (ML) to genome-wide data from 41,686 individuals in the largest European consortium on Alzheimer's disease (AD) to investigate the effectiveness of various ML algorithms in replicating known findings, discovering novel loci, and predicting individuals at risk. We utilised Gradient Boosting Machines (GBMs), biological pathway-informed Neural Networks (NNs), and Model-based Multifactor Dimensionality Reduction (MB-MDR) models. ML approaches successfully captured all genome-wide significant genetic variants identified in the training set and 22% of associations from larger meta-analyses. They highlight 6 novel loci which replicate in an external dataset, including variants which map to ARHGAP25, LY6H, COG7, SOD1 and ZNF597. They further identify novel association in AP4E1, refining the genetic landscape of the known SPPL2A locus. Our results demonstrate that machine learning methods can achieve predictive performance comparable to classical approaches in genetic epidemiology and have the potential to uncover novel loci that remain undetected by traditional GWAS. These insights provide a complementary avenue for advancing the understanding of AD genetics., Wethank the University of Lille’s Intensive Scientific Computing Mesocentre. M.B.S. and V.E.P. are supported by the UK Dementia Research Institute [UK DRI-3206] through UK DRI Ltd, principally funded by the Medical Research Council and by the UK Medica Research Council: MR/ T04604X/1, MR/P005748/1. K.V.S. has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreements No 813533 (MLFPM) and No 860895 (TranSYS), and FNRS convention PDR T.0294.24 “Expanded PRS embracing pathways and interactions for increased clinical utility”.F.M.(FedericoMelograna)wasalsofundedby the Marie Sklodowska-Curie grant agreement 860895 (TranSYS). J.W. (Julie Williams) is supported by Moondance Dementia Research Laboratory. B.M.T. and G.R. (Gennady Roshchupkin) are funded by ZonMw VIDI (#09150171910068) and ZonMw Veni grant (1936320) respectively.N.A.isfundedbyGSK.RGandADweresupportedbythe Italian Ministry of Health (Ricerca Corrente)., Peer reviewed
UPCommons. Portal del coneixement obert de la UPC
Publication Artículo científico (JournalArticle)

MONFIT: multi-omics factorization-based integration of time-series data sheds light on Parkinson’s disease

  • Mihajlović, Katarina
  • Malod-Dognin, Noël
  • Ameli, Corrado
  • Skupin, Alexander
  • Pržulj, Nataša
Parkinson’s disease (PD) is a severe and complex multifactorial neurodegenerative disease with still elusive pathophysiology preventing the development of curative treatments. Molecular deep phenotyping by longitudinal multi-omics is a promising approach to identify mechanisms of PD aetiology and its progression. However, the heterogeneous data require new analysis frameworks to understand disease progression across biological entities and processes. Here, we present MONFIT, a holistic analysis pipeline that integrates and mines time-series single-cell RNA-sequencing data with bulk proteomics and metabolomics data by non-negative matrix tri-factorization, enabling prior knowledge incorporation from molecular networks. First, MONIFT integrates time-point-specific data and then holistically mines the integrated data across time points. By applying MONFIT to longitudinal multi-omics data of differentiation of PD and control patient-derived induced pluripotent stem cells into dopaminergic neurons, we identify novel PD-associated genes, emphasize molecular pathways that play important roles in PD pathology and suggest new intervention opportunities using drug-repurposing. MONFIT is fully adaptable to other multi-omics data sets., European Union’s EU Framework Programme for Research and Innovation Horizon 2020 [860895]; European Research Council (ERC) Consolidator Grant [770827]; Spanish State Research Agency and the Ministry of Science and Innovation MCIN [PID2022-141920NB-I00/AEI/10.13039/501100011033/FEDER, UE]; Department of Research and Universities of the Generalitat de Catalunya code [2021 SGR 01536]., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publication Artículo científico (JournalArticle)

Multi-omics integration of scRNA-seq time series data predicts new intervention points for Parkinson’s disease

  • Mihajlović, Katarina
  • Ceddia, Gaia
  • Malod Dognin, Noël
  • Novak, Gabriela
  • Kyriakis, Dimitrios
  • Skupin, Alexander
  • Przulj, Natasa|||0000-0002-1290-853X
Parkinson’s disease (PD) is a complex neurodegenerative disorder without a cure. The onset of PD symptoms corresponds to 50% loss of midbrain dopaminergic (mDA) neurons, limiting early-stage understanding of PD. To shed light on early PD development, we study time series scRNA-seq datasets of mDA neurons obtained from patient-derived induced pluripotent stem cell differentiation. We develop a new data integration method based on Non-negative Matrix Tri-Factorization that integrates these datasets with molecular interaction networks, producing condition-specific “gene embeddings”. By mining these embeddings, we predict 193 PD-related genes that are largely supported (49.7%) in the literature and are specific to the investigated PINK1 mutation. Enrichment analysis in Kyoto Encyclopedia of Genes and Genomes pathways highlights 10 PD-related molecular mechanisms perturbed during early PD development. Finally, investigating the top 20 prioritized genes reveals 12 previously unrecognized genes associated with PD that represent interesting drug targets., This project has received funding from the European Union’s EU Framework Programme for Research and Innovation Horizon 2020, Grant Agreement No 860895, the European Research Council (ERC) Consolidator Grant 770827, the Spanish State Research Agency and the Ministry of Science and Innovation MCIN grant PID2019-105500GB-I00 / AEI / 10.13039/501100011033 and grant PID2022-141920NB-I00 / AEI /10.13039/501100011033/ FEDER, UE, and the Department of Research and Universities of the Generalitat de Catalunya code 2021 SGR 01536. DK was supported by the PRIDE program of the Luxembourg National Research Fund through PRIDE17/12244779/PARK-QC., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

MONFIT: multi-omics factorization-based integration of time-series data sheds light on Parkinson’s disease

  • Mihajlović, Katarina
  • Malod-Dognin, Noël
  • Ameli, Corrado
  • Skupin, Alexander
  • Pržulj, Nataša
Parkinson’s disease (PD) is a severe and complex multifactorial neurodegenerative disease with still elusive pathophysiology preventing the development of curative treatments. Molecular deep phenotyping by longitudinal multi-omics is a promising approach to identify mechanisms of PD aetiology and its progression. However, the heterogeneous data require new analysis frameworks to understand disease progression across biological entities and processes. Here, we present MONFIT, a holistic analysis pipeline that integrates and mines time-series single-cell RNA-sequencing data with bulk proteomics and metabolomics data by non-negative matrix tri-factorization, enabling prior knowledge incorporation from molecular networks. First, MONIFT integrates time-point-specific data and then holistically mines the integrated data across time points. By applying MONFIT to longitudinal multi-omics data of differentiation of PD and control patient-derived induced pluripotent stem cells into dopaminergic neurons, we identify novel PD-associated genes, emphasize molecular pathways that play important roles in PD pathology and suggest new intervention opportunities using drug-repurposing. MONFIT is fully adaptable to other multi-omics data sets., European Union’s EU Framework Programme for Research and Innovation Horizon 2020 [860895]; European Research Council (ERC) Consolidator Grant [770827]; Spanish State Research Agency and the Ministry of Science and Innovation MCIN [PID2022-141920NB-I00/AEI/10.13039/501100011033/FEDER, UE]; Department of Research and Universities of the Generalitat de Catalunya code [2021 SGR 01536]., Peer Reviewed, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Multi-omics integration of scRNA-seq time series data predicts new intervention points for Parkinson’s disease

  • Mihajlović, Katarina
  • Ceddia, Gaia
  • Malod Dognin, Noël
  • Novak, Gabriela
  • Kyriakis, Dimitrios
  • Skupin, Alexander
  • Przulj, Natasa
Parkinson’s disease (PD) is a complex neurodegenerative disorder without a cure. The onset of PD symptoms corresponds to 50% loss of midbrain dopaminergic (mDA) neurons, limiting early-stage understanding of PD. To shed light on early PD development, we study time series scRNA-seq datasets of mDA neurons obtained from patient-derived induced pluripotent stem cell differentiation. We develop a new data integration method based on Non-negative Matrix Tri-Factorization that integrates these datasets with molecular interaction networks, producing condition-specific “gene embeddings”. By mining these embeddings, we predict 193 PD-related genes that are largely supported (49.7%) in the literature and are specific to the investigated PINK1 mutation. Enrichment analysis in Kyoto Encyclopedia of Genes and Genomes pathways highlights 10 PD-related molecular mechanisms perturbed during early PD development. Finally, investigating the top 20 prioritized genes reveals 12 previously unrecognized genes associated with PD that represent interesting drug targets., This project has received funding from the European Union’s EU Framework Programme for Research and Innovation Horizon 2020, Grant Agreement No 860895, the European Research Council (ERC) Consolidator Grant 770827, the Spanish State Research Agency and the Ministry of Science and Innovation MCIN grant PID2019-105500GB-I00 / AEI / 10.13039/501100011033 and grant PID2022-141920NB-I00 / AEI /10.13039/501100011033/ FEDER, UE, and the Department of Research and Universities of the Generalitat de Catalunya code 2021 SGR 01536. DK was supported by the PRIDE program of the Luxembourg National Research Fund through PRIDE17/12244779/PARK-QC., Peer Reviewed, Postprint (published version)